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Introduction
The landscape of oncological practice has substantially changed 
with the introduction of immune checkpoint inhibitors that target 
inhibitory receptors on the surface of CD8+ T cells (1). In particu-
lar, blocking of the inhibitory receptor programmed death 1 (PD-1) 
or its ligand PD-L1 has been shown to induce durable responses 
across many different cancer types, including non–small cell lung 
cancer (NSCLC), melanoma, squamous carcinoma of the head 
and neck, kidney cancer, and ovarian cancer (1, 2). However, most 
patients have primary resistance to therapeutic PD-1 or PD-L1 
blockade or develop secondary resistance (2). Thus, identification 
of additional pathways mediating suppression of tumor-specific T 
cells is clearly needed to increase therapeutic efficacy of PD-1– or 
PD-L1–targeting strategies.
Pattern recognition receptors (PRRs), such as Toll-like recep-
tors or nucleotide-binding oligomerization domain–like (NOD-
like) receptors, detect pathogens or danger signals, and engage-
ment of these PRRs by pathogen-associated molecular patterns 
(PAMPs) or damage-associated molecular patterns (DAMPs) 
activates the respective immune cells (3–6). Receptors that bind 
to PAMPs and DAMPs have also been implicated in cancer pro-
gression and anticancer immunity (6, 7). In addition to these 
well-described pathways, sialoglycans have been shown to serve 
as a self-associated molecular patterns (SAMPs) by binding to 
CD33-related sialic acid–binding immunoglobulin-like lectins 
(CD33rSiglecs) (8, 9), a family of receptors on immune cells con-
taining intracellular immunoreceptor tyrosine-based inhibitory 
motifs (ITIM) (10–13). Unlike the conserved Siglecs (Siglec-1, 
Siglec-2, Siglec-4, and Siglec-15), CD33rSiglecs, including Siglec-3 
(CD33), Siglec-5, Siglec-6, Siglec-7, Siglec-8, Siglec-9, Siglec-10, 
Siglec-11, Siglec-14, and Siglec-16, have evolved rapidly due to 
multiple selection forces, including evolutionary pressure by 
pathogens that can mimic sialoglycan-SAMPs (Sia-SAMPs) and 
bind to inhibitory CD33rSiglecs to escape innate immune control 
(14–18). The different Siglecs have different binding preferenc-
es for sialoglycan ligands (9). While Siglec-8 has a more defined 
spectrum of ligands, which include 6′-sulfo-sialyl Lewis x (19, 
20), Siglec-9 has a much broader binding spectrum of sialylated 
ligands (9, 21). Siglec-9 is therefore a typical PRR for Sia-SAMPs.
Recent evidence suggests that the upregulation of Sia-SAMPs 
can facilitate evasion of immune control during cancer progression 
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There was a significant increase of Sia-SAMPs (Siglec-7 and 
Siglec-9 ligands) in lung carcinomas compared with healthy lung 
tissue as well as in acute and chronic inflammatory diseases, 
as assessed with Siglec-Fc proteins (Figure 1, H and I). Ligands 
were strongly present on cytokeratin-positive cells, suggesting 
they were in a trans position, and a trend toward an increase in 
ligands at higher stages was observed (Supplemental Figure 1L). 
As Siglec-9 was the most prominent and consistent inhibitory 
CD33rSiglec upregulated on TILs across different patients, we 
focused our further analysis on Siglec-9.
Characterization of Siglec-9–expressing intratumoral CD8+ T 
cells. We aimed to further characterize the Sig9+CD8+ TILs in 
samples from NSCLC patients by multicolor flow cytometry. 
Sig9+CD8+ TILs coexpressed several other inhibitory receptors, 
including PD-1 in particular and also TIM-3 and LAG-3 (Figure 2, 
A–D, and Supplemental Figure 2, A–D). Most Sig9+CD8+ TILs were 
found within the population with the highest PD-1 expression 
(PD-1hi, Supplemental Figure 2A). However, not all the PD-1hiCD8+ 
T cells expressed Siglec-9 (Supplemental Figure 2B), suggesting 
that Sig9+CD8+ TILs are a subpopulation of tumor-specific PD-1hi 
TILs. Sig9+CD8+ T cells also expressed high levels of the tran-
scription factor Eomesodermin (Eomeshi) and low levels of T-bet 
(T-betlo, Supplemental Figure 2E). In general, Sig9+CD8+ TILs had 
more inhibitory receptors upregulated and coexpressed than Sig9–
CD8+ TILs from NSCLC patients (Figure 2E). Several costimula-
tory receptors were also enriched on Sig9+CD8+ TILs as compared 
with Sig9–CD8+ TILs (Supplemental Figure 2, F–J). RNA sequenc-
ing (RNA-seq) revealed that several genes were differentially reg-
ulated between Sig9+CD8+ TILs and Sig9–CD8+ TILs (Supplemen-
tal Figure 2K). The 3 main genes upregulated in Sig9+CD8+ TILs 
were SPP1 (osteopontin), Ki67, and KLF4 (Figure 2F). We also 
looked for the expression of genes involved in the generation of 
Sia-SAMPs. Expression of the rate-limiting enzyme for sialic acid 
biosynthesis, UDP-N-acetylglucosamine-2-epimerase (GNE), was 
higher in Sig9+CD8+ TILs than in Sig9–CD8+ TILs (Supplemen-
tal Figure 2L). Consequently, an upregulation of sialoglycans, as 
shown by increased staining with Sambucus nigra lectin (SNA) 
(Supplemental Figure 2M), and an upregulation of cis ligands on 
TILs, as shown by increased staining with Siglec-9-Fc protein, 
occurred (Supplemental Figure 2N). Protein levels of osteopontin 
(SPP1) ( Supplemental Figure 2, O and P) and Ki-67 (Supplemental 
Figure 2Q) were also significantly higher in Sig9+CD8+ TILs than 
in Sig9–CD8+ TILs (Supplemental Figure 3 shows the gating strate-
gy for sorting of primary T cells from tumor samples).
Sig9+ TILs are a distinct subset within the CD8+ T cell population. 
We further tested to determine whether Siglecs are upregulated by 
activation of T cells. While Siglec-5 expression increased signifi-
cantly on polyclonally activated CD8+ T cells from healthy donors, 
Siglec-9 was only slightly upregulated and Siglec-7 expression was 
unchanged (Supplemental Figure 4A). Antigen-specific stimula-
tion of T cell clones with reactivity against peptides from influen-
za antigens, CMV antigens, and melanA led to a slight upregula-
tion of Siglec-9 (Supplemental Figure 4B). Sig9+CD8+ TILs from 
NSCLC samples activated with anti-CD3/anti-CD28 antibodies 
expressed significantly higher surface levels of CD25 (Figure 3A), 
CD69 (Figure 3B), and the newly identified activation marker 
Siglec-5 (Supplemental Figure 4C) compared with similarly acti-
by engaging inhibitory CD33rSiglecs, such as Siglec-7 and Siglec-9 
(21–26). Engagement of Siglec-7 and Siglec-9 inhibits NK cell–
mediated tumor cell killing in vitro (22, 23). Siglec-9 and its murine 
functional paralog Siglec-E have also been implicated in myeloid 
cell–mediated cancer progression (21, 24). Binding of the cancer- 
associated sialylated glycoform of MUC1 to Siglec-9 on macro-
phages can induce a tumor-associated macrophage (TAM) pheno-
type that can promote cancer progression and immune evasion (25).
In chronic infections and cancer, expression of checkpoint 
molecules, including PD-1, CTLA-4, TIM-3, and LAG-3, is 
observed on T cells and is associated with a state of T cell dys-
function termed T cell exhaustion (27). Chronic infections, such 
as HIV, have also been shown to upregulate inhibitory CD33r-
Siglecs on peripheral CD4+ T cells, which suggests that inhibito-
ry Siglec receptors might be involved in T cell immunoregulation 
(28). In contrast, previous analyses have found very low expres-
sion of CD33rSiglecs on peripheral T cells of healthy humans (29) 
and mice (30). We therefore sought to characterize Siglec expres-
sion on tumor-infiltrating T cells and to test the functional role of 
Siglecs as new potential immune checkpoints that are regulated by 
glycans within the tumor microenvironment.
Results
Siglec-9 is upregulated on tumor-infiltrating T cells. We analyzed 
the expression of inhibitory CD33rSiglecs on immune cells 
in primary NSCLC samples (Supplemental Figure 1A; supple-
mental material available online with this article; https://doi.
org/10.1172/JCI120612DS1). As previously described, CD33r-
Siglecs, including Siglec-7 and Siglec-9, were expressed on NK 
cells and Siglec-9 was also expressed on myeloid cells (Supple-
mental Figure 1B). Several inhibitory CD33rSiglecs, including 
Siglec-3 (CD33), Siglec-5, Siglec-7, Siglec-10, and Siglec-9, were 
expressed on a significant proportion of tumor-infiltrating lym-
phocytes (TILs), including CD4+ and CD8+ T cells (Figure 1, A–G, 
and Supplemental Figure 1, C–F). Siglec-9 was the most prom-
inently and consistently expressed CD33rSiglec on TILs across 
patients (Figure 1G). Lower levels of Siglec-9 were observed on 
peripheral blood T cells from healthy donors (Figure 1, A–C) or 
in spleens from patients undergoing splenectomy for nonmalig-
nant disease (Supplemental Figure 1G). There were a few healthy 
donors that had a larger population of Siglec-9–expressing CD8+ 
T cells (Figure 1C). In order to further understand the heteroge-
neity of Siglec-9 expression, we further stained for Siglec-9 in 
an additional and better-characterized population of 49 healthy 
donors (Supplemental Figure 1H). The distribution of Siglec-9 
on CD8+ T cells was similar in both cohorts, and no correlation 
with age could be seen (Supplemental Figure 1I). No significant 
difference was seen between sexes (9% in men, 7.2% in women 
Sig9+CD8+ T cells of total CD8+ T cells). We found an inverse cor-
relation of Sig9+CD8+ with naive CCR7+CD45RA+ T cells (Supple-
mental Figure 1J). Immunostaining of intratumoral leukocytes 
showed that Siglec-9 was typically expressed on small lympho-
cytes and macrophages (Figure 1E). Double staining showed that 
Siglec-9–positive TILs in NSCLC samples also expressed CD3 
(Figure 1F). We also found an upregulation of Siglec-9 on col-
orectal cancer (CRC) and epithelial ovarian cancer (EOC) TILs 
or pleural effusions (Supplemental Figure 1K).
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Figure 1. Siglec-9 is upregulated on CD8+ TILs. (A) Representative flow cytometry analysis of 
Siglec-9 expression on CD8+ T cells in PBMCs from healthy donors (left panel), PBMCs from NSCLC 
patients (middle panel), and TILs from a matched NSCLC patient (right panel). (B and C) Quanti-
fication of Siglec-9 expression on CD4+ (B) and CD8+ (C) TILs from NSCLC patients (PBMCs, n = 36; 
NSCLC, n = 41; mean ± SD). Statistical analysis by unpaired Student’s t test. (D) Paired analysis of 
CD8+ T cells from the peripheral blood and tumors of NSCLC patients (n = 20). Statistical analysis 
by paired Student’s t test. (E) Immunohistochemical staining of Siglec-9–positive cells in NSCLC 
sections. Scale bars: 50 μm. (F) Representative immunofluorescence analysis of CD3 and Siglec-9 
double-positive cells and Siglec-9 staining or SNA staining and Siglec-9 staining (right panel). Scale 
bars: 30 μm (left panel); 50 μm (right panel).(G) Heatmap of expression analysis of different Siglecs 
in NSCLC samples on CD4+ and CD8+ TILs. (H and I) Immunofluorescence study in paraffin-embedded 
tissue microarrays using recombinant Siglec-9–Fc (human IgG1) fusion protein coupled to secondary 
PE-conjugated (Fab′)2 goat anti-human Fc antibody. Representative images (H) and Siglec ligands 
quantification summary (I) are shown. Original magnification, ×400. Scale bars: 50 μm. Fluorescence 
values were normalized against an IgG1 isotype control. Lung tissue, n = 5; adjacent lung tissue,  
n = 9; squamous cell carcinoma (SCC), n = 20; adenocarcinoma, n = 20; small cell lung cancer (SCLC), 
n = 10; broncho-alveolar carcinoma (BAC), n = 10; atypical carcinoid, n = 5. Data are shown as mean ± 
SEM. Statistical analysis performed by 1-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001.
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with WT A549 cells (Figure 4B). Feeding GNE-KO A549 cells 
with N-acetylneuraminic acid (Neu5Ac) to metabolically bypass 
the mutation led to a recovery of ligands on the cell surface and 
binding to Siglec-9 (Figure 4B). CD8+ T cell–mediated tumor cell 
killing was tested by coincubation of T cells from healthy donors 
and different A549 tumor cell variants in the presence of a CD3/
EpCAM T cell–bispecific (TCB) antibody (catumaxomab). T cell–
mediated killing of GNE-KO A549 cells and desialylated A549 
cells was higher compared with that of WT A549 cells and GNE-
KO A549 cells fed with Neu5Ac (Figure 4C). Similar results were 
obtained with catumaxomab when using HT29 tumor cells (Sup-
plemental Figure 7C and Figure 4D) and TILs obtained from pri-
mary NSCLC samples together with A549 and HT29 cells (Figure 
4, E and F). Experiments with the anti-CD3/CD19 TCB antibody 
blinatumomab and CD19+ Ramos cells (Figure 4G and Supple-
mental Figure 7D) or primary CLL samples (Figure 4H) showed 
similar results. Sig9+CD8+ T cells from NSCLC TILs were signifi-
cantly more reactive toward GNE-KO A549 cells than Sig9– TILs, 
with the difference being sialic acid dependent (Figure 4I). Sim-
ilarly, Sig9+CD8+ T cells induced more apoptosis in HT-29 and 
Ramos cells, respectively, than Sig9–CD8+ T cells (Supplemental 
Figure 7, E and F).
To test the effect of Siglec-9 blockade on T cell activation in 
vitro, we used a Siglec-9 antibody and the previously described 
staphylococcal enterotoxin B (SEB) test (32). Two full IgG Siglec-9 
antibodies (191240 and E10-286) inhibited T cell activation and 
therefore were agonistic (Supplemental Figure 7, G and H). More-
over, Siglec-9 antibodies led to a dose-dependent inhibition of T 
cell activation tested by upregulation of the activation markers 
CD25 (Figure 4J) and CD69 (Supplemental Figure 7I). Addition of 
the Siglec-9 antibody (clone 191240) inhibited IL-2 production and 
CD69 expression on the surface of TILs upon SEB stimulation of 
vated Sig9–CD8+ TILs. Similar results were seen for polyclonally 
activated peripheral Sig9+CD8+ cells from healthy donors (Supple-
mental Figure 4, D–G). CD8+ T cells from NSCLC samples were 
clearly dysfunctional or exhausted, as demonstrated by reduced 
production of cytokines such as IFN-γ and TNF-α compared with 
that of CD8+ T cells from healthy donor peripheral blood mononu-
clear cells (PBMCs) (Figure 3, C and D). However, restimulation 
of TILs from NSCLC patients with anti-CD3/anti-CD28 antibod-
ies showed that Sig9+CD8+ TILs were much easier to restimulate 
and secrete at higher levels of multiple cytokines, including IFN-γ, 
than Sig9–CD8+ TILs (Figure 3, C and D, Supplemental Figure 5, 
A–N). In addition, Sig9+CD8+ cells expressed a distinct pattern of 
chemokine receptors, including CXCR3, CXCR5, CCR4, CCR6, 
and CX3CR1 (Supplemental Figure 5, O–T). A recent study also 
found a subpopulation of PD-1hiCD8+ TILs with a distinct, high-
er functionality (31); this subpopulation was associated with an 
increased expression of CD5 and a lower expression of CD38 and 
CD101 (31). We therefore stained for these markers and found 
an enrichment of CD5 and Ki67 expression (Figure 3, E and F) 
on Sig9+ cells in the PD-1hi gate as well as a reduced presence of 
CD38+ and CD101+ (Figure 3G, Supplemental Figure 6). Our data 
provide evidence that intratumoral Sig9+CD8+ cells are a distinct 
subpopulation of tumor-specific CD8+ TILs.
Sia-SAMP/Siglec-9 interaction is a target for improving T cell 
activation. Next, we wanted to explore the functional implica-
tion of Siglec expression on T cells. We used the high-affinity 
CD33rSiglec ligand LGALS3BP, which is upregulated in NSCLC 
(24). LGALS3BP inhibited CD8+ T cell activation in a sialic acid–
dependent fashion (Figure 4A, Supplemental Figure 7, A and B). 
We further generated cell lines that expressed lower surface lev-
els of Sia-SAMPs by knocking out GNE. GNE-deficient A549 lung 
adenocarcinoma cells showed lower binding to Siglec-9 compared 
Figure 2. Sig9+CD8+ TILs coexpress inhibitory receptors. (A and B) Expression of PD-1 in primary NSCLC samples on Sig9–CD8+ (Sig9–) or Sig9+CD8+ (Sig9+) 
TILs (A, n = 44) and representative FACS analysis (B). Statistical analysis by paired Student’s t test. (C and D) Expression of TIM-3 (C, n = 71) and LAG-3 
(D, n = 18) on Sig9–CD8+ or Sig9+CD8+ TILs from NSCLC samples. Statistical analysis by paired Student’s t test. (E) Analysis of the number of coexpressed 
inhibitory receptors on Sig9–CD8+ or Sig9+CD8+ TILs. (F) Volcano plot of RNA-seq on sorted TILs according to their Siglec-9 expression. The 3 significantly 
differentially expressed genes were MIK67 (Ki67), KLF4, and SPP1. *P < 0.05; ***P < 0.001. Data are presented as mean ± SD.
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than on SigE–CD8+ TILs (Figure 5, C–F, and Supplemental Figure 
8, F and G). SigE+CD8+ TILs were predominantly terminally dif-
ferentiated Eomeshi, Tbetlo, and CD127+ T cells (Supplemental Fig-
ure 8H). Sorted murine SigE+CD8+ TILs again showed a stronger 
reactivation than SigE–CD8+ TILs, as shown by upregulation of the 
activation markers CD25 and CD69 (Figure 5G). Taken together, 
these findings suggest that SigE+CD8+ TILs in mice are phenotypi-
cally similar to Sig9+CD8+ TILs in humans.
Sia-SAMPs mediate immune escape in vivo. To further inves-
tigate the role of Sia-SAMPs in immune evasion, we generated 
GNE-deficient MC38 cells and compared their subcutaneous 
growth with that of WT MC38 tumor cells. GNE-KO MC38 tumors 
showed a clear delay in tumor growth compared with WT MC38 
tumors injected subcutaneously in C57BL/6 mice (Figure 5H). 
Similar observations were made for GNE-KO and WT EMT6 
tumors injected subcutaneously into BALB/c mice (Figure 5I). 
The GNE-KO cell lines showed no growth differences or survival 
differences in vitro (Supplemental Figure 8I). The frequencies of 
CD3+, CD8+, and CD4+ T cells in leukocyte infiltrates were signifi-
cantly higher in GNE-KO MC38 tumors compared with WT MC38 
tumors (Figure 5, J and K, and Supplemental Figure 8J), whereas 
there was no difference in the infiltration of regulatory T cells (Sup-
plemental Figure 8J). GNE-KO tumor infiltrates also contained 
more classical dendritic cells (CD11c+MHCII+ cells within CD45+ 
cells) than WT MC38 tumors, whereas other myeloid cell types did 
not differ significantly (Supplemental Figure 8J). In order to ana-
lyze the role of adaptive immunity, we repeated the experiment in 
primary NSCLC samples (Figure 4, K and L). We hypothesized that 
bivalent binding and subsequent dimerization of Siglec-9 might 
be responsible for the agonistic effect on Siglec-9 by the clone 
191240. Indeed, monovalent carbohydrate-recognition domain–
blocking (CRD-blocking) Fab fragments from clone 191240 (Sup-
plemental Figure 7J) significantly increased IL-2 (Figure 4K), but 
not CD69 (Figure 4L), production upon SEB stimulation. These 
findings demonstrate that T cell activation in NSCLC tumors can 
be increased by targeting Sia-SAMPs/Siglec-9 interactions.
Siglec-E is expressed on TILs in mice. We further investigated 
whether the murine functionally equivalent paralog (Siglec-E) 
was upregulated on TILs in mouse models. We found a significant 
upregulation of Siglec-E on murine CD8+ TILs when compared 
with splenocytes from control mice and tumor-bearing mice in the 
MC38 subcutaneous tumor model (Figure 5A) and other models 
(LLC, B16, and EMT6 subcutaneous tumor models; Supplemen-
tal Figure 8A). While other inhibitory CD33rSiglecs, including 
Siglec-F and Siglec-G, were also upregulated on the surface of 
murine TILs, Siglec-E was the most prominently upregulated 
inhibitory Siglec tested (Supplemental Figure 8B). We further ana-
lyzed the phenotype of SigE+CD8+ murine TILs. The proliferation 
marker Ki67, the activation markers granzyme B and CD69, and 
the activating receptor CD27 (Figure 5B, and Supplemental Figure 
8, C–E) were all significantly increased on murine SigE+CD8+ TILs 
compared with SigE–CD8+ TILs, similarly to what is seen in human 
TIL samples. The expression and number of murine inhibitory 
receptors, including PD-1, were also higher on SigE+CD8+ TILs 
Figure 3. Sig9+CD8+ TILs are a distinct subset within intratumoral CD8+ T cells. (A and B) Upregulation of the activation markers CD25 (A) and CD69 (B) on 
Sig9–CD8+ or Sig9+ TILs sorted from primary NSCLC samples and activated with anti-CD3/28 antibodies for 48 hours (n = 9). Statistical analysis by paired 
Student’s t test. (C) ELISA analysis of IFN-γ in the supernatant of sorted Sig9–CD8+ T cells or Sig9+CD8+ T cells (n = 3–7, independent patients). Cells were 
sorted from PBMCs of healthy donors or primary NSCLC samples (TILs). Act, activated. Supernatants from 50,000 cells were analyzed. (D) Analysis of 
TNF-α in the supernatant of sorted Sig9–CD8+ or Sig9+CD8+ cells from healthy donors or NSCLC patient samples (n = 3–7, independent donors/patients). 
Statistical analysis performed by 1-way ANOVA. (E) Expression level of CD5 in the CD8+PD-1hi population on Sig9– TILs and Sig9+ TILs (n = 9). (F) Percentage 
of Sig9–CD8+ TILs or Sig9+CD8+ TILs in primary NSCLC samples that express Ki67 within the PD-1hi population (n = 9). (G) Frequency of CD38hiCD101hi cells on 
Sig9– and Sig9+CD8+PD-1hi TILs determined by flow cytometric analysis (n = 13). Statistical analysis by paired Student’s t test. *P < 0.05; **P < 0.01;  
***P < 0.001. Data are presented as mean ± SD.
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mice deficient for the adaptive immune system (NOD scid gamma 
[NSG] mice). Both MC38 and EMT6 GNE-KO cell lines showed no 
growth difference when compared with WT cell lines in NSG mice 
(Supplemental Figure 8K). From these findings, we concluded the 
sialylation directly affects tumor growth and also the antitumor 
immune response by enhancing the adaptive immune response to 
cancer (Supplemental Figure 9 shows the gating strategy for deter-
mining Siglec-E expression on tumor-infiltrating T cells).
Expression of Siglec receptors on T cells directly modulate antitu-
mor immunity. To further investigate the role of Sia-SAMPs and 
their interactions with CD33rSiglecs, we used a human Siglec-9 
transgenic mouse (HS9) that allows selective expression of 
Siglec-9 in cells producing Cre recombinase (21). Previous analy-
sis demonstrated that human Siglec-9 binds to ligands on murine 
tumor cells (21). HS9 mice were crossed with CD4-Cre mice to 
express human Siglec-9 in T cells. These mice expressed Siglec-9 
in both CD4+ and CD8+ T cells (Supplemental Figure 10A). The 
growth of syngeneic MC38 tumor cells was accelerated in mice 
expressing Siglec-9 in T cells, and the tumors grew larger com-
pared with those in littermate control mice (Figure 6A). This find-
ing supports the hypothesis that inhibitory Siglecs on T cells can 
mediate immune evasion. We also used the recently developed 
Siglec-E16 (SigE16) transgenic mice (18). These mice express a 
chimeric Siglec receptor with the extracellular domain of Siglec-E 
and the transmembrane and intracellular domain of the activating 
human Siglec-16 receptor under the Siglec-E promoter (18). No 
major differences were observed between the frequency of naive 
and memory T cells in different genetic animal models (Supple-
mental Figure 10B). Siglec-E expression in WT and SigE16 mice 
was similar (Supplemental Figure 10C). Compared with those 
in WT littermate control mice, subcutaneous syngeneic MC38 
tumors grew more slowly and remained smaller in homozygous 
Figure 4. Sia-SAMPs inhibit T cell–mediated tumor cell killing in vitro. (A) Inhibition of T cell activation by LGALS3BP in a dose-dependent manner mea-
sured by intracellular IFN-γ by flow cytometry. CD8+ T cells from healthy donors were activated with anti-CD3 and anti-CD28 antibodies in the presence 
of increasing amounts of LGALS3BP (μg/ml, n = 3). (B) Representative histograms of binding of Sig9-Fc to A549 WT cells, enzymatically desialylated 
A549 cells (desia), GNE-deficient A549 cells (GNE-KO), and GNE-KO A549 cells refed with 10 mM Neu5Ac. (C) Percentage of cleaved caspase-3–positive 
(clCasp3+) WT A549 cells, desialylated A549 cells, GNE-KO A549 cells, or GNE-KO A549 cells fed with Neu5Ac (refed) after incubation with CD8+ T cells and 
catumaxomab (n = 10). (D) Apoptosis of WT, desialylated, GNE-KO, and refed GNE-KO HT-29 cells measured by upregulation of cleaved caspase-3 in tumor 
cells (n = 6). (E and F) clCaps3+ A549 (E, n = 11) or HT-29 (F, n = 11) tumor cells after coincubation with TILs from NSCLC or CRC samples. (G) CD8+ T cells were 
sorted according to their Siglec-9 expression and incubated with either WT or GNE-KO A549 cells (n = 4). (H) CD19+ RAMOS cells were incubated with CD8+ 
T cells from healthy donors in the presence of CD3 and CD19 bispecific antibody blinatumomab (n = 7). (I) GNE-KO RAMOS cells incubated with CD8+ T cells 
from patients with chronic lymphocytic leukemia (n = 3). (J) Activation measured by CD25 on CD8+ T cells treated with anti-CD3 and anti-CD28 antibodies 
in the presence of anti–Siglec-9 antibody (clone 191240, g/ml, n = 4). (K) Relative IL-2 production of NSCLC primary tumor samples incubated with SEB and 
Siglec-9–blocking antibody and the Fab fragments (clone 191240, n = 5). (L) Measurement of CD69 upregulation on CD8+ TILs from NSCLC patients upon 
incubation with SEB in the presence of antibodies or Fab fragments (n = 5). Statistical analyses in this figure were performed by 1-way ANOVA. Data are 
presented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001.
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SigE16 mice (Figure 6B). MC38 tumors had an increased induc-
tion of antitumor antibodies (Supplemental Figure 10D). Deple-
tion experiments demonstrated the dependence of the effect on 
both CD4+ and CD8+ T cells and directly showed that the genetic 
reversal of an inhibitory into an activating Siglec receptor can also 
influence T cell activation (Figure 6, C and D). We also used an 
adoptive transfer model to study the role of Siglec-E on T cells. We 
transferred OT-I T cells expressing either WT Siglec-E or activat-
ing SigE16 into WT mice with OVA-expressing MC38-OVA tumors 
and measured the growth of tumors. MC38-OVA tumors in mice 
transferred with OT-I from SigE16 mice had significantly reduced 
tumor growth (Figure 6E). In addition, OT-I T cells expressing 
SigE16 had increased proliferation (Supplemental Figure 10E). 
In addition, a trend toward increased infiltration was also seen in 
mice adoptively transferred with SigE16-expressing OT-I T cells 
(Supplemental Figure 10F). To determine the effect of sialogly-
cans in trans position on the growth difference in SigE16 mice, we 
used MC38 WT and GNE-KO cells. The previous growth differ-
ence could no longer be seen in the SigE16 background (Supple-
mental Figure 10G). This finding suggests that the effect seen in 
SigE16 mice is mediated by interactions of trans ligands with acti-
vating SigE16 receptor.
Sig9+ TILs and Siglec-9 polymorphisms are associated with clinical 
end points. We further analyzed the correlation of Siglec expres-
sion on T cells with clinical parameters. Patients with a high fre-
quency of Sig9+ TILs (>30% of CD8+ T cells) had significantly 
worse overall survival (Figure 6F). The significance was slightly 
reduced in a multivariate analysis taking age and also stage into 
account (P = 0.0668 with a hazard ratio of 14.6 by a Cox propor-
tional hazard regression analysis). Recently, polymorphisms of 
Siglec-9 were associated with pulmonary diseases (33). We stud-
ied to determine whether the risk of developing lung cancer was 
associated with the rs2075803 and rs2258983 polymorphisms 
in the TRICL4 cohort (34). The risk of developing squamous cell 
lung cancer was significantly reduced in the presence of these 
polymorphisms (Table 1). We also examined the polymorphisms 
rs2075803 and rs2258983 in 3,795 cases of CRC and 3,044 con-
trols to estimate the relative risk of developing CRC. Individuals 
Figure 5. Sialylated SAMPs enhance immune escape and tumor growth in vivo. (A) Siglec-E expression was determined by flow cytometry on control 
splenocytes, splenocytes from tumor-bearing mice, and CD8+ TILs from subcutaneous MC38 tumors (n = 25–28). Statistical analysis performed by 1-way 
ANOVA. (B) Expression of intracellular Ki67 was examined by flow cytometry on SigE–CD8+ and SigE+CD8+ TILs (n = 18). Statistical analysis by paired 
Student’s t test. (C–E) Frequencies of inhibitory immune receptor expression on SigE–CD8+ and SigE+CD8+ TILs from MC38 tumors, as studied by flow 
cytometry. PD-1 (C, n = 16), TIM-3 (D, n = 18), and LAG-3 (E, n = 7) were analyzed. Statistical analysis by paired Student’s t test. (F) Number of coexpressed 
inhibitory receptors on SigE–CD8+ or SigE+CD8+ TILs. (G) Upregulation of CD25+CD69+ upon restimulation of sorted SigE–CD8+ and SigE+CD8+ TILs. Statistical 
analysis by paired Student’s t test. (H) Growth curves of subcutaneous WT or GNE-KO MC38 tumors (n = 8–9). (I) Growth curves of subcutaneous WT and 
GNE-KO EMT6 tumors (n = 13-14). Experiments were replicated 2 to 3 times. Statistical analysis by 2-way ANOVA. (J and K) Frequencies of CD3+ and CD8+ 
cells in the tumor (n = 7). Statistical analysis by unpaired Student’s t test. **P < 0.01; ***P < 0.001. Data are presented as mean ± SD.
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How Siglec-9 is upregulated on TILs and how Siglecs are reg-
ulated in T cells, including intracellular signaling, remain unclear. 
We observed only a slight upregulation of Siglec-9 upon polyclonal 
and antigen-specific stimulation of healthy T cells. Other immune 
checkpoint receptors are upregulated through repetitive antigenic 
stimulation or the tumor microenvironment, including inhibito-
ry cytokines (27). We have seen a similar effect in several mouse 
models, indicating that the mechanism for Siglec upregulation in 
T cells appears to be conserved across species, even though Siglec 
receptors have diverged quite a lot between mice and humans. We 
observed a heterogeneity of the frequency in Sig9+CD8+ T cells in 
the peripheral blood of healthy donors and an inverse correlation 
with the frequency of naive CD8+ T cells. This finding suggests 
that healthy individuals with more circulating peripheral memory 
T cells also have a higher number of Sig9+CD8+ T cells. Until now, 
mainly Siglec-9–expressing NK cells and myelomonocytic cells 
have been associated with immune modulation in cancer. Myeloid 
cells were more reactive in a mouse model of Siglec-E deficiency, 
and increased immunosurveillance was observed in these mice 
(21). Engagement of Siglec-9 on monocytes/macrophages by a 
cancer-associated, sialylated glycoform of MUC1 showed polar-
ization toward immune-suppressive TAMs with upregulation of 
PD-L1 (25). Two analyses examined the function of inhibitory 
Siglec-7 and Siglec-9 in NK cell–mediated tumor cell killing (22, 
23). Other immune receptors, including PD-1, are also expressed 
who were homozygous A for the rs2075803 SNP and homozygous 
C for the rs2258983 SNP had a significantly reduced risk of devel-
oping CRC (Supplemental Table 1).
Discussion
Recent studies have shown that inhibitory CD33rSiglecs can 
modulate the interactions of immune cells with tumor cells by 
sialic acid–dependent mechanisms (21–23, 25, 26), raising the 
possibility that these Siglecs could be used for therapeutic check-
point inhibition, analogous to the remarkable recent therapeutics 
directed against PD-1 or CTLA-4 (2). We and others have shown 
that T cells from healthy humans express low levels of CD33- 
related Siglecs (29, 35). However, we show here that expression 
of the inhibitory Siglec-9 is clearly increased on CD4+ and CD8+ 
TILs compared with peripheral T cells from healthy donors. We 
also observed the presence of Siglec ligands in both cis and trans 
positions. In addition, we confirmed previous observations that 
have shown a small population of peripheral T cells with Siglec-7 
and Siglec-9 expression (35). Properly glycosylated CD52 has pre-
viously been identified as a ligand for Siglec-10 on human T cells 
(36). Furthermore, inhibitory mouse Siglec-G (often referred to 
as the murine paralog of human Siglec-10) was found to inhibit 
DAMP-associated T cell activation (37). These investigations 
demonstrate that Siglecs can dampen T cell responses in the con-
text of general inflammation.
Figure 6. Engagement of inhibitory Siglecs on T cells mediates immune escape. (A) Subcutaneous growth curves of MC38 tumors in littermate Siglec-9 
transgenic control mice (HS9) or Siglec-9 transgenic mice crossed to CD4-Cre mice (HS9, CD4Cre) (n = 8–10). The experiment was repeated 3 times. Statis-
tical analysis by 2-way ANOVA. (B) Tumor volumes after 21 days of subcutaneous MC38 tumors in littermate control mice (E/E) or homozygous (E16/E16) 
mice that express the chimeric receptor SigE16 (n = 7). Statistical analysis performed by 1-way ANOVA. (C) Subcutaneous growth curves of MC38 tumors 
in E16 mice or littermate control mice after CD4 and CD8 cell depletion by antibodies (n = 7–8). The experiment was repeated 2 times. Statistical analysis 
by 2-way ANOVA. (D) MC38 tumor volumes after 21 days in E16 mice and littermate control mice and independent depletion of CD4+ and CD8+ T cells. (E) 
Tumor volume of MC38-OVA tumors after adoptive transfer of OVA-specific OT-I CD8+ T cells from WT or SigE16 (E16) mice. Statistical analysis performed 
by 1-way ANOVA. *P < 0.05; **P < 0.01. Data are presented as mean ± SD. (F) Survival analysis of NSCLC patients with low (n = 18) and high percentage 
(above 30%, n = 11) of Siglec-9 expression on their CD8+ T cells. Differences were analyzed by Wilcoxon’s test. A multivariate analysis of the 2 groups for 
age and stage showed slightly reduced significance, with a P value of 0.0669 (multivariate, univariate analysis P = 0.0097) and a hazard ratio of 14.6.
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to the activation of Siglec-9 signaling by dimerization. In con-
trast, the use of monovalent Fab fragments of the antibody clone 
191240, which inhibits Sia-SAMP/Siglec-9 interactions by ham-
pering ligand binding to the CRD, led to increased T cell activa-
tion. This result suggests that the Sia-SAMP/Siglec-9 interaction 
can be targeted for the enhancement of TIL activation in lung 
tumors. Functional relevance is further supported by the analy-
sis of a Siglec-9 polymorphism in cancer patients. This shows an 
association of hypomorphic alleles with the risk of developing 
squamous NSCLC. In addition, the same alleles were also associ-
ated with the risk for CRC. These polymorphisms were previous-
ly associated with an increased frequency of pulmonary emphy-
sema, exacerbations of chronic obstructive pulmonary disease, 
and a hyperactive immune response of myeloid cells (33). While 
the function of these polymorphisms needs to be tested in T cells, 
their linkage to disease outcome suggests a role for Siglec-9 in the 
development of lung and CRC.
Our studies also show that the inhibitory Siglec-E receptor, the 
functional paralog of Siglec-9 and Sia-SAMPs in the tumor, influ-
ences the T cell–mediated immune response to tumors in mouse 
models. Reduction of Sia-SAMPs by using GNE-KO tumor cell lines 
led to a reduced growth of tumors. In particular, the use of the more 
antigenic cell line EMT6-HER2 showed rejection of the tumors in 
some mice when hyposialylated GNE-KO tumor cells were used. 
The KO of GNE in those cell lines most likely induces additional 
changes in glycosylation besides reducing the level of sialylation. 
An upregulation of polylactosamine could change the interaction 
with other immune-modulatory lectins, such as galectins (44). 
Also, during the growth of tumors in mice, the cells could potential-
ly acquire sialic acids from the host. Nevertheless, we observed a 
relevant growth difference in 2 different models. Previous experi-
ments with B16 melanoma cell lines have also shown similar results, 
although different approaches were used for the reduction of tumor 
sialylation (45). Another analysis with hyposialylated methyl-
cholanthrene-induced (MCA-induced) tumors has shown growth 
inhibition of subcutaneous tumors (46). Overexpression of inhibito-
ry Siglec-9 on CD4+ and CD8+ T cells led to increased tumor growth, 
which indicates a functional role of inhibitory Siglecs on T cells. 
Exchange of inhibitory Siglec-E with activating SigE16 (extracellu-
lar Siglec-E domain with transcellular activating human Siglec-16) 
showed T cell–dependent growth inhibition. In an adoptive trans-
fer model, we demonstrated that Siglec-E on T cells is functionally 
involved, although the model we used, with OVA-specific OT-I T 
on myeloid cells and NK cells within the tumor (38, 39). Further 
experiments are needed to understand the functional relevance of 
these immune-modulatory receptors, including Siglec-9 or PD-1, 
on cell types other than T cells. However, it is likely that CD8+ T 
cells continue to play central roles in cancer immunotherapy, and 
we define Siglec-9 on CD8+ TILs as a potential therapeutic target 
for cancer immunotherapy.
Further characterization of Sig9+CD8+ TILs revealed that these 
cells coexpress several inhibitory receptors, including PD-1, TIM-3, 
Lag3, and others. Our analysis suggests that Sig9+CD8+ TILs are a 
subpopulation of CD8+PD-1hi TILs, which are often tumor-specific 
(40). Coexpression of multiple inhibitory receptors on T cells and 
also PD-1hi TILs was associated with an exhaustion phenotype in 
cancer, including in patients with NSCLC (27, 41). Indeed, func-
tional analysis of TILs from NSCLC patients showed a significantly 
reduced capacity to produce cytokines and chemokines (Figure 3). 
However, Sig9+CD8+ T cells from NSCLC patients were easier to 
reactivate than Sig9–CD8+ T cells despite the increased expression 
of PD-1 and other inhibitory immune receptors on Sig9+ TILs. This 
finding suggests that Sig9+CD8+ TILs belong to a specific subtype 
within PD-1hi TILs. A recent analysis of chromatin states in murine 
and human TILs from melanoma and NSCLC patients demonstrat-
ed a subpopulation within PD-1hi TILs that had a relatively higher 
expression of CD5 and lower expression of CD38 and CD101 and 
that showed a greater potential for reprogrammability and reactiva-
tion (31). Our findings showed an enrichment of high CD5 expres-
sion and low CD38 and CD101 expression on Sig9+CD8+ TILs in 
the PD-1hi gate. This finding could be interpreted as an overlap of 
Sig9+CD8+ TILs with this previously described tumor-specific TIL 
subpopulation that could be potentially reactivated by immuno-
therapy. Other studies have also shown that, not only exhausted 
TILs coexpress a high frequency of inhibitory receptors, but also 
activated TILs (42). This could mean that the Sig9+CD8+ TILs are 
in a higher activation state that could potentially be uncovered by 
blocking these different inhibitory receptors (43).
Our analysis also includes functional studies both in vitro with 
human tissue and in vivo in different mouse models to demon-
strate the relevance of inhibitory Siglecs on TILs and their inter-
actions with cancer-associated Sia-SAMPs. The previous studies 
have provided evidence that Sia-SAMP/Siglec interactions can 
inhibit immune cell activation in in vitro models (21–23, 25). The 
use of bivalent anti–Siglec-9 antibodies (clones 191240 and E10-
286) led to an inhibition of T cell activation, which might be due 
Table 1. Risk for lung cancer depending on Siglec-9 polymorphisms
rs Number Reference allele Effect allele OR 95% CI (L) 95% CI (U) P value
NSCLC rs2075803 A G 0.998 0.963 1.035 0.92
NSCLC rs2258983 C A 0.998 0.962 1.035 0.91
Adenocarcinoma rs2075803 A G 1.03 0.974 1.09 0.29
Adenocarcinoma rs2258983 C A 1.036 0.978 1.097 0.23
Squamous rs2075803 A G 0.939 0.888 0.993 0.027
Squamous rs2258983 C A 0.936 0.884 0.991 0.023
95%CI (L), 95% lower CI; 95%CI (U), 95% upper CI. P value by Cox proportional regression analysis, multivariate analysis for age, sex, and top significant 
principal components from previous studies.
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anti–Siglec-9 antibody (R&D Systems). T cell activation was assessed 
by FACS staining, and IL-2 secretion was measured in the supernatant 
by ELISA (BioLegend).
RNA-seq and analysis. CD8+ TILs were sorted from frozen NSCLC 
samples by FACS according to their Siglec-9 expression. Gates used 
were as follows: lymphocytes, singlets, DAPI–CD3+, and CD8+CD4–. 
RNA was isolated and the library prepared by Microsynth AG. 
Next-generation sequencing of the library and data analysis were 
performed by Microsynth AG. Count data from RNA-seq samples 
were analyzed using the edgeR Bioconductor package in R. Filtered 
genes, expressed at more than 1 count per million (cpm) in at least 3 
samples, were analyzed using the QLF functions with batch correction 
for patients. All genes were ranked according to their F statistics com-
paring Siglec-9–positive and –negative samples. A weighted gene set 
enrichment analysis (GSEA) was performed using this preranked list 
using the GSEA java application (http://www.broad.mit.edu/gsea/). 
Box plots comparing expression levels between Siglec-9–positive and 
–negative cells were performed in R using logarithmically transformed 
cpm values. All original microarray data were deposited in the NCBI’s 
Gene Expression Omnibus database (GEO GSE115305).
GNE-deficient cells and in vitro tumor cell killing with CD3/EpCAM 
TCB or CD3/CD19 TCB. Human and murine GNE-deficient tumor cell 
lines were created using CRISPR/CAS9. Guide RNAs were designed 
online using e-crisp.org, synthesized by Microsynth AG, and cloned 
into the pX458 vector (Addgene). A549, HT-29, and RAMOS cell lines 
were bought from ATCC. After transient transfection in tumor cells, 
single-cell sorting and subsequent screening for cell-surface sialyla-
tion were performed. Multiple GNE-deficient clones were pooled in 
order to avoid clonal selection when comparing with WT cell lines.
GNE-deficient cell lines and cell lines were refed with 5 mM 
Neu5Ac for 24 hours. Coincubation with magnetically isolated CD8+ 
T cells from healthy donors or tumor samples in the presence of 
catumaxomab (anti-CD3/anti-EpCAM; Fresnius) or blinatumomab, 
(anti-CD3/anti-CD19; Amgen) was performed at a concentration of 
10 ng/ml. Alternatively, the respective cell lines were stained with 
carboxyfluorescein succinimidyl ester (CSFE) (Sigma-Aldrich) and 
spiked into full-tumor digests obtained from primary NSCLC or CRC 
samples. Tumor cell killing was analyzed by FACS staining for cleaved 
caspase-3 and by staining with the LIVE/DEAD Viability/Cytotoxicity 
Kit (Thermo Fisher Scientific). Tumor cells were gated by size and 
expression of EpCAM or CD19, respectively, as well as by negative 
gating using CD3, CD8, and CD4.
Genetic mouse models for in vivo analysis of Siglec function on T cells. 
Siglec-9 transgenic mice were described previously (21). Siglec-9 
transgenic mice (B6.Cg-Tg[CAG-Siglec-9]1Avrk) were crossed with 
CD4-Cre mice (B6Tg[CD4-cre]1Cwi) to obtain a T cell–specific over-
expression of inhibitory human Siglec-9 in the C57BL/6 background. 
Transgenic mice expressing SigE16 chimeric Siglec-E with trans-
membrane and intracellular domain of activating human Siglec-16 
(B6.Cg-Siglece < tm4E16Avrk>) were also described previously (18). 
Tumor cell lines were injected into 8- to 12-week-old female mice, and 
tumor growth was monitored as described above.
SigE16 was crossed into OT-I transgenic mice. For the adoptive 
transfer of OVA-specific OT-I cells from WT or SigE16 mice, T cells 
were harvested from splenocytes and injected into WT C57BL/6 mice 
bearing subcutaneous MC38-OVA tumors. T cells were followed for 
proliferation by labeling with Cell Trace Violet (CTV) (Thermo Fish-
cells, has certain limitations and OVA is not directly comparable to 
naturally occurring tumor antigens.
Cancer immunotherapy and, in particular, checkpoint block-
ade with inhibitors of the PD-1/PD-L1/L2 axis and CTLA-4 are 
now routinely used in daily oncological practice (1, 47). However, 
only a minority of cancer patients show objective responses under 
checkpoint blockade and only a few develop long-term remissions. 
Thus, combination therapies are a promising approach to improv-
ing response rates of immunotherapies and outcomes for patients 
(48, 49). Our data suggest that targeting the Sia-SAMP/Siglec-9 
pathway could improve antitumor immunity and define this path-
way as an inhibitory immune checkpoint for T cell activation.
Methods
Patients and sample preparation. Surgical specimens were mechanical-
ly dissociated, digested with accutase (PAA Laboratories), collagenase 
IV (Worthington), hyaluronidase (MilliporeSigma), and DNAse type I 
(MilliporeSigma), filtered, washed, and frozen for future use. Single- 
cell suspensions were prepared. Human PBMCs were isolated by den-
sity gradient centrifugation using Histopaque-1077 (MilliporeSigma) 
from buffy coats obtained from healthy blood donors (Blood Bank, 
University Hospital Basel). Single-cell suspensions and PBMCs were 
frozen for later use in liquid nitrogen.
Multicolor flow cytometry. For multicolor flow cytometry, dead cells 
were stained using LIVE/DEAD Fixable Blue Dye (Invitrogen) and 
various panels of antibodies. Doublets were excluded in all analyses. 
Corresponding isotype antibodies or fluorescence-minus-one (FMO) 
samples were used as a control, in particular for the Siglec staining. All 
tumor samples were analyzed with a Fortessa LSR II Flow Cytometer 
(BD Biosciences). For infiltration analysis, mice were euthanized and 
tumors were mechanically dissociated and digested as described for 
the human sample preparation.
Staining for Siglec-7 and Siglec-9 ligands on tumor microarray. Tis-
sue microarrays from US Biomax were used for screening of Siglec-9 
ligand expression in lung cancer samples. For immunofluorescence 
staining, recombinant human Siglec-hFcs (R&D Systems) were mixed 
with PE-conjugated anti-human IgG (Jackson ImmunoResearch Lab-
oratories) for 1 hour at 4°C prior to use. For the specific visualization of 
cancer cells, Anti–Multi-Cytokeratin (Leica Biosystems) staining was 
performed and visualized with a goat anti-mouse IgG coupled to Alexa 
Fluor 488 (Life Technologies). The general fluorescence per sample 
was measured in a ScanRI Microarray Scanner (PerkinElmer) and pro-
cessed with ImageJ software, version 1.48 (NIH). Pictures were taken 
using a fluorescence microscope with original magnification of ×400 
(Zeiss). Fluorescence was quantified using ImageJ software and nor-
malized to background staining (secondary antibody only).
In vitro T cell activation and inhibition. Murine and human T cells 
were polyclonally stimulated with anti-CD3 and anti-CD28 antibod-
ies (BioLegend). Anti-CD3 antibodies (0.5 μg/ml) were either coated 
overnight at 4°C for human T cells or added for mouse T cells. Anti-
CD28 was added at 1 μg/ml. For inhibition assays with sialylated 
LGALS3BP, LGALS3BP was coated overnight as well. Activation of 
T cells was determined by staining for activation and proliferation 
markers by flow cytometry or measuring cytokines in supernatants by 
ELISA. For the SEB assay, primary NSCLC samples were incubated at 
200,000 cells/well with SEB (10 ng/ml, MilliporeSigma) for 48 hours 
in the presence of full-length or digested Fab fragments of the 191240 
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15–106). Informed consent was obtained from all patients prior to the 
sample collection. Mouse experiments were approved by the local 
committee of Basel Stadt (approval number 2747).
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combine the summary data from each association test. Meta-analysis 
was performed using SAS version 9.4 (SAS Institute Inc.). For the anal-
ysis of an association of Siglec-9 polymorphisms with the risk of CRC, 
SNP genotypes for rs2075803 and rs2258983 among cases and con-
trols from imputed genotype data derived from samples genotyped 
on the Oncoarray platform and USC Norris Cancer Center were used. 
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multivariate analysis was done by Cox proportional hazard analysis. P 
< 0.05 was considered statistically significant.
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